Please ensure Javascript is enabled for purposes of website accessibility

Allergan's Credit Rating Appears Safe -- Is Its Stock?

By Todd Campbell - Apr 14, 2016 at 9:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Moody's reports it believes Allergan will maintain its investment-grade rating, but there could still be risk associated with buying Allergan's stock.

SOURCE: FLICKR USER PICTURES OF MONEY.

Earlier today, credit-ratings service Moody's (MCO 0.01%) issued a report that says it believes Allergan plc.'s (AGN) cash flow, and the potential for $36 billion in after-tax money tied to the sale of its generics business to Teva Pharmaceutical (TEVA -5.41%), will protect its investment-grade credit rating, except under certain circumstances. Despite Moody's assurances, shares in Allergan dropped today to new lows following the demise of its planned tie-up with big pharma giant Pfizer. Is Allergan's financial picture really safe, and if it is, are its shares a buy?

AGN Chart

AGN data by YCharts.

A bit of background
Allergan is a global pharmaceuticals company that has built up market-leading positions in eye care and treatment for central nervous system disorders, such as depression, and Alzheimer's disease. The company's $15 billion in 2015 sales, and low-tax Irish domicile, prompted Pfizer to agree to merge with it last year in a $160 billion combination.

At the time, Pfizer cited Allergan's top-selling drugs, such as Botox, its product pipeline, and tax savings, as reasons for merging; however, after the U.S. Treasury Department announced new rules that would prohibit Pfizer from moving its headquarters overseas to cut its tax bill, Pfizer and Allergan scuttled their merger plans.

Since then, Allergan's shares have fallen sharply over concerns regarding its $42 billion in debt, its limited cash cushion, and the potential risk that regulators could block its planned deal with Teva Pharmaceutical.

Offering up some clarity
Moody's indicates that it believes Allergan's financial situation is OK, as long as the deal with Teva Pharmaceutical goes as planned. Allergan agreed to sell its generic drug business to Teva Pharmaceutical last summer for $33.75 billion in cash, and $6.75 billion in Teva Pharmaceutical's stock. As a result, Allergan estimates that it will walk away with $36 billion in after-tax monies that it can use to reduce debt, acquire competitors, or fund share buybacks.

Moody's says that Allergan could keep its investment-grade rating as long as it uses that money for small-to-midsize acquisitions rather than debt-fueled megadeals, and it avoids stock repurchases without a commensurate reduction in its debt. According to Moody's analysis, Allergan's credit rating could remain top shelf even if it spent as much as $30 billion on an acquisition, as long as the deal is financed largely with cash, and the company being acquired is EBITDA positive.

One big question mark
The key to Allergan's rating, however, appears to be its receiving a cash windfall from Teva Pharmaceutical. In that regard, regulators at the Federal Trade Commission could be a fly in the ointment. Although regulators in the EU signed off on the Teva Pharmaceutical deal earlier this year, the FTC has yet to formerly give the two companies its OK.

Allergan's management is confident that it will get the regulatory go-ahead, and that it will close this deal before midyear. Until the FTC officially gives its blessing, however, investors are likely to discount Allergan's share price.

Looking forward
Investors may not be totally off-base to think that regulators could balk at giving these two generics businesses a green light to combine. After all, generic drug price increases have drawn considerable fire in the past year, and regulators could view this merger as being too anti-competitive.

That worry creates uncertainty that forces investors to consider how Allergan might fare if the Teva Pharmaceutical deal disintegrates. On that basis, its heavy debt load and $1.2 billion cash stockpile seem a bit lacking. Moody's report may also be dashing some hope of a big share buyback that could prop up its flagging share price.

Nevertheless, Allergan's shares could offer investors opportunity if prices slide below $200, and get closer to its book value of $181. After all, Allergan's balance sheet will look a lot better if the deal goes through, and even if the deal falls apart, Allergan could still spin off the business in an IPO. Regardless, I'm content to sit on the sidelines for now until there's more clarity.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.43 (2.92%) $1.49
Allergan plc Stock Quote
Allergan plc
AGN
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.52 (-5.41%) $0.43
Moody's Corporation Stock Quote
Moody's Corporation
MCO
$271.97 (0.01%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.